Journal of Clinical Oncology recognizes that readers do not always have time to review an article in depth, and yet they still wish to understand how the results will influence their clinical practice or research. To address this need, we offer podcasts that will enhance the readership experience by presenting the key results of high-profile publications in a convenient audio format. Our podcasts are designed to place selected articles into a clinically useful perspective that is easy to listen to in the office or while on the road.
By Reed Drews. This JCO Podcast provides observations and
commentary on the JCO article, "Safety and Efficacy of TG101348, a
Selective JAK2 Inhibitor, in Myelofibrosis" by authors Animesh
Pardanani, et al.
About the Podcast
The Journal of Clinical Oncology (JCO) serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. Usually presented in conjunction with an original report and an editorial published on www.jco.org, the JCO podcasts enable readers to stay current on the latest research while placing the results into a clinically useful context.